Company Name
Jiangsu Hengrui Medicine Co., Ltd.
Year of Establishment
1970
Enterprise Size
more than 500
Annual Turnover(USD)
More than 1000,000,000
Company Introduction
Jiangsu Hengrui Medicine Co., Ltd., established in 1970, having over 17,000 employees globally, is the largest manufacturer of antineoplastic drgus, surgical drugs and contrast media in China. Its operating income was over USD 2.4 billion in 2017. The company stock was officially listed on the Shanghai Stock Exchange in 2000. All APIs and finish dosage forms have passed national GMP authentication. For APIs, we got approvals from US-FDA, EDQM, PMDA and TGA. For FDFs, we got approvals from US-FDA, EU and PMDA.
Main Competitive Advantages
Brandname,International Approvals/Standards,Experienced R&D Staff,Delivery Term,Production capacity,Large Product Line,Buyers Specifications Accepted,Small Orders Accepted,Reputation,Quality Service,
Website
http://www.hrs.com.cn/
Other Competitive Advantages
Milestone
1970: Hengrui Medicine's predecessor---Lianyungang Pharmaceutical Factory was established.
1984: Hengrui Medicine's first anticancer drug---Etoposide API and drug product were put into production.
1995: APIs of Etoposide and Ifosfamide passed US FDA inspection.
1997: Jiangsu Hengrui Medicine Co., Ltd. was incorporated.
1999: No.1 Finished Product Plant was put into use in Lianyungang.
2000: Shanghai Hengrui Pharmaceutical Co., Ltd. was established.
2005: USA branch HENGRUI (USA) Ltd. was established.
2006: Oxaliplatin API got CEP certificate.
Callisyn Biomedical-Suzhou was established.
2008: New API manufacturing plant in Lianyungang was put into production.
2010: Irinotecan HCl API passed Japanese PMDA inspection.
2011: Chengdu Suncadia Pharmaceuticals Co., Ltd. was established.
2012: First injectable product Irinotecan HCl Injection was launched in US market.
2013: Innovative medicine HR8735, SHR0534 IND obtain permissions for clinical trials in USA.
2014: Japanese branch Hengrui Medical Japan Corp. was established.
Finished product Cyclophosphamide for Injection was launched in US and EU market.
Subsidiary company Cadiasun Pharman GmbH was formally established in Germany.
Hengrui's innovative drug "Methanesulfonic Acid Apatinib Tablet" was approved by CFDA of China.
2015: Suzhou Suncadia Biopharmaceutical Co., Ltd. was established.
Irinotecan for Injection was launched in Japanese market.
Incyte, a US-based biotechnology firm licensed the global commericial rights for Hengrui's PD-1 antibody for $795M.
2016: Sevoflurane Inhalation Anaesthetic was launched in EU and US. Desflurane Inhalation and Caspofungin Acetate for Injection received Netherlands GMP certificate.